Patents by Inventor Susan Margaret Mitchell

Susan Margaret Mitchell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240052426
    Abstract: The present invention relates generally to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset or predisposition to die onset of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or adenocarcinoma. The DNA methylation status of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in DNA methylation of one or more nucleic acid molecules.
    Type: Application
    Filed: May 4, 2023
    Publication date: February 15, 2024
    Inventors: Jason Peter Ross, Horace Drew, Michael Buckley, Peter Laurence Molloy, Susan Margaret Mitchell, Konsta Rainer Duesing, Zheng-Zhou Xu
  • Patent number: 10889852
    Abstract: Provided herein are methods for identifying sites and regions within a gene or genome that are amenable to analysis of methylation. The methods disclosed herein allow the efficient identification on a genome-wide scale of target restriction sites and fragments that provide targets for subsequent analysis.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: January 12, 2021
    Assignee: Commonwealth Scientific and Industrial Research Organisation
    Inventors: Peter Molloy, Susan Margaret Mitchell, Konsta Duesing
  • Publication number: 20200172963
    Abstract: The present invention relates generally to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset or predisposition to the onset of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset and/or progression of a large intestine or breast neoplasm, such as an adenoma or adenocarcinoma. The DNA methylation status of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal or breast neoplasms, such as colorectal or breast adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in DNA methylation of one or more nucleic acid molecules.
    Type: Application
    Filed: November 14, 2019
    Publication date: June 4, 2020
    Inventors: Peter Laurence Molloy, Lawrence Charles Lapointe, Susanne Kartin Pedersen, Susan Margaret Mitchell
  • Patent number: 10526642
    Abstract: The present invention relates generally to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset or predisposition to the onset of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset and/or progression of a large intestine or breast neoplasm, such as an adenoma or adenocarcinoma. The DNA methylation status of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal or breast neoplasms, such as colorectal or breast adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in DNA methylation of one or more nucleic acid molecules.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: January 7, 2020
    Assignees: Commonwealth Scientific and Industrial Research Organisation, Clinical Genomics Pty. Ltd.
    Inventors: Peter Laurence Molloy, Lawrence Charles Lapointe, Susanne Kartin Pedersen, Susan Margaret Mitchell
  • Publication number: 20140315203
    Abstract: The present invention relates generally to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset or predisposition to the onset of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset and/or progression of a large intestine or breast neoplasm, such as an adenoma or adenocarcinoma. The DNA methylation status of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal or breast neoplasms, such as colorectal or breast adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in DNA methylation of one or more nucleic acid molecules.
    Type: Application
    Filed: August 24, 2012
    Publication date: October 23, 2014
    Applicants: Commonwealth Scientific and Industrial Research Organisation, Clinical Genomics Pty. Ltd.
    Inventors: Peter Laurence Molloy, Lawrence Charles Lapointe, Susanne Kartin Pedersen, Susan Margaret Mitchell
  • Publication number: 20130338020
    Abstract: The present invention relates generally to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset or predisposition to the onset of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or adenocarcinoma. The DNA methylation status of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in DNA methylation of one or more nucleic acid molecules.
    Type: Application
    Filed: September 13, 2011
    Publication date: December 19, 2013
    Applicants: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION, CLINICAL GENOMICS PTY. LTD.
    Inventors: Jason Peter Ross, Michael Buckley, Peter Laurence Molloy, Susan Margaret Mitchell, Konsta Rainer Duesing, Zheng-Zhou Xu